Sarepta, BioMarin Sign Licensing Deal

Sarepta, BioMarin Sign Licensing Deal

Sarepta Therapeutics and BioMarin signed a license agreement regarding exon-skipping technology and settled a patent dispute. The license agreement gives Sarepta global exclusive rights to BioMarin’s Duchenne muscular dystrophy patient database for its Exondys 51 product, which uses Sarepta’s exon-skipping technology, which allows cells to jump through faulty sections of genetic code and and all future exon-skipping products, the companies said on Tuesday. BioMarin retains the right to convert the […]

Read More ˃